Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 1;6(3):100998.
doi: 10.1016/j.jhepr.2023.100998. eCollection 2024 Mar.

Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease

Anne Linde Mak  1   2 , Nienke Wassenaar  3   4 , Anne-Marieke van Dijk  1   2 , Marian Troelstra  3 , Veera Houttu  1   2 , Koen van Son  1   2   5 , Stan Driessen  1   2 , Diona Zwirs  1 , Sandra van den Berg-Faay  3 , Elizabeth Shumbayawonda  6 , Jurgen Runge  7   3 , Michail Doukas  8 , Joanne Verheij  2   9 , Ulrich Beuers  10 , Max Nieuwdorp  1   2 , Djuna L Cahen  11 , Aart Nederveen  3 , Oliver Gurney-Champion  3   4 , Adriaan Holleboom  1   2
Affiliations

Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease

Anne Linde Mak et al. JHEP Rep. .

Abstract

Background & aims: Individuals with obesity may develop intrapancreatic fat deposition (IPFD) and fatty pancreas disease (FPD). Whether this causes inflammation and fibrosis and leads to pancreatic dysfunction is less established than for liver damage in metabolic dysfunction-associated steatotic liver disease (MASLD). Moreover, the interrelations of FPD and MASLD are poorly understood. Therefore, we aimed to assess IPFD and fibro-inflammation in relation to pancreatic function and liver disease severity in individuals with MASLD.

Methods: Seventy-six participants from the Amsterdam MASLD-MASH cohort (ANCHOR) study underwent liver biopsy and multiparametric MRI of the liver and pancreas, consisting of proton-density fat fraction sequences, T1 mapping and intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI).

Results: The prevalence of FPD was 37.3%. There was a clear correlation between pancreatic T1 relaxation time, which indicates fibro-inflammation, and parameters of glycemic dysregulation, namely HbA1c (R = 0.59; p <0.001), fasting glucose (R = 0.51; p <0.001) and the presence of type 2 diabetes (mean 802.0 ms vs. 733.6 ms; p <0.05). In contrast, there was no relation between IPFD and hepatic fat content (R = 0.03; p = 0.80). Pancreatic IVIM diffusion (IVIM-D) was lower in advanced liver fibrosis (p <0.05) and pancreatic perfusion (IVIM-f), reflecting vessel density, inversely correlated to histological MASLD activity (p <0.05).

Conclusions: Consistent relations exist between pancreatic fibro-inflammation on MRI and endocrine function in individuals with MASLD. However, despite shared dysmetabolic drivers, our study suggests IPFD is a separate pathophysiological process from MASLD.

Impact and implications: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and 68% of people with type 2 diabetes have MASLD. However, fat infiltration and inflammation in the pancreas are understudied in individuals with MASLD. In this cross-sectional MRI study, we found no relationship between fat accumulation in the pancreas and liver in a cohort of patients with MASLD. However, our results show that inflammatory and fibrotic processes in the pancreas may be interrelated to features of type 2 diabetes and to the severity of liver disease in patients with MASLD. Overall, the results suggest that pancreatic endocrine dysfunction in individuals with MASLD may be more related to glucotoxicity than to lipotoxicity.

Clinical trial number: NTR7191 (Dutch Trial Register).

Keywords: MASH; MASLD; fatty pancreas disease; multiparametric MRI; pancreatic steatosis.

PubMed Disclaimer

Conflict of interest statement

ES is employed by Perspectum Ltd., who provided some of the MRI protocols used for the multiparametric MRI data reported in this paper. All other authors declare no conflicts of interest. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
The T1 relaxation time of the pancreas is higher in individuals with impaired glucose control. (A) Type 2 diabetes. Level of significance: p = 0.03 (t-test). (B) Fasting glucose levels. Level of significance: p = 0.0012 (Spearman’s rho). (C) HbA1c. Level of significance: p = 0.0023 (Spearman’s rho).
Fig. 2
Fig. 2
Fat content of the pancreas is not related to the fat content of the liver. Both pancreatic and liver fat content are displayed as assessed by PDFF. Level of significance: p = 0.9 (Spearman’s rho). Dashed line represents the FPD cut-off of 6.2%. FPD, fatty pancreas disease; PDFF, proton-density fat fraction.
Fig. 3
Fig. 3
Relations between pancreatic fat content and liver histology scores. (A) Pancreatic fat content is unrelated to liver steatosis grade. Level of significance: p = 0.82 (Kruskall-Wallis test). (B) Pancreatic fat content does not differ between SAF inflammatory activity grades. Level of significance: p = 0.95 (Kruskall-Wallis test). (C) Pancreatic fat content is unrelated to hepatic fibrosis stage. Level of significance: p = 0.23 (Mann-Whitney U test). Dashed line represents the FPD cut-off of 6.2%. FPD, fatty pancreas disease.
Fig. 4
Fig. 4
Pancreatic IVIM diffusion is lower in individuals with advanced hepatic fibrosis. Level of significance: p = 0.028 (t-test). IVIM, intravoxel incoherent motion.
See this image and copyright information in PMC

References

    1. Smits M.M., Van Geenen E.J.M. The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol. 2011;8(3):169–177. - PubMed
    1. Petrov M.S., Taylor R. Intra-pancreatic fat deposition: bringing hidden fat to the fore. Nat Rev Gastroenterol Hepatol. 2022 Mar;19(3):153–168. - PubMed
    1. Filippatos T.D., Alexakis K., Mavrikaki V., et al. Nonalcoholic fatty pancreas disease: role in metabolic syndrome, “Prediabetes,” diabetes and atherosclerosis. Dig Dis Sci. 2022 Jan;67(1):26–41. - PubMed
    1. Singh R.G., Yoon H.D., Wu L.M., et al. Ectopic fat accumulation in the pancreas and its clinical relevance: a systematic review, meta-analysis, and meta-regression. Metabolism. 2017 Apr;69:1–13. - PubMed
    1. Rinella M.E., Lazarus J.V., Ratziu V., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;(23):S0168–S8278. doi: 10.1016/j.jhep.2023.06.003. 00418-X. - DOI - PubMed

LinkOut - more resources